v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT05305560 |
Full text link
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Jan. 8, 2023, midnight Source : ClinicalTrials.gov |
|
Contact
Last imported at : Jan. 8, 2023, midnight Source : ClinicalTrials.gov |
Not reported |
Registration date
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
2022-03-31 |
Recruitment status
Last imported at : Jan. 8, 2023, midnight Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Prevention |
Inclusion criteria
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria: age between 18 and 65 years, inclusive. body weight >45 kg. body mass index >18.5. close contact with a person who has a pcr-confirmed sars-cov-2 infection within 5 days before screening. only one member in the same household will be enrolled. participants must be able to give informed consent and comply with the study's scheduled events/visits and study assessments. sars-cov-2 positive index case must be able to give consent to enable collection of the documented positive pcr test. female participants of childbearing potential must use a highly effective method of contraception for the duration of the trial. |
Exclusion criteria
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
pregnant or breast-feeding. participants who have been administered covid-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study. a positive covid-19 result (pcr or antigen test) within 8 days of screening. presence of typical covid-19 symptoms (fever >38°c, spo2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening. hypersensitivity to any component of ivermectin. participants who have been administered ivermectin within 30 days prior to screening. participation in another interventional trial within the last 30 days or 5 half-lives of the imp of the other trial, whichever comes first. participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.). history of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors. current use of monoclonal antibodies for the treatment of covid-19. |
Number of arms
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
MedinCell S.A |
Inclusion age min
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
65 |
Countries
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Bulgaria |
Type of patients
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Close contacts to covid patients |
Severity scale
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
N/A |
Total sample size
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
400 |
primary outcome
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
COVID-19 prophylaxis |
Notes
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : April 1, 2022, 3:30 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "nan", "treatment_id": 693, "treatment_name": "Ivermectin", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |